VRN101099, Brain Permeable HER2 Kinase Inhibitor, Shows the Anti-tumor Activity in Preclinical Models of HER2-positive Cancers

被引：0
|
作者：
Ko, Yikyung
Yoo, Jihye
Jung, Hong-Ryul
Lim, Hyerim
Lee, YeongDeok
Kim, Se Hyuk
Shin, Dong Guk
Cho, Serin
Heo, Myung Hoe
Kim, Haelee
Cho, Ha Yeon
Han, Ah Reum
Ko, Eunhwa
Choi, Hwan Geun
Kim, Deakwon
Kim, Sunghwan
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-11-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-03
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Preclinical development of a novel biparatopic HER2 antibody with activity in low to high HER2 expressing cancers
    Weisser, Nina
    Wickman, Grant
    Davies, Rupert
    Rowse, Gerry
    CANCER RESEARCH, 2017, 77
  • [22] HER2 Staining Intensity Shows Prognostic Impact on Patients with HER2-Positive Invasive Breast Cancer
    Chen, Yen-Ying
    Hsu, Chih-yi
    MODERN PATHOLOGY, 2018, 31 : 53 - 54
  • [23] HER2 Staining Intensity Shows Prognostic Impact on Patients with HER2-Positive Invasive Breast Cancer
    Chen, Yen-Ying
    Hsu, Chih-Yi
    LABORATORY INVESTIGATION, 2018, 98 : 53 - 54
  • [24] Preclinical evaluation of eFT226, a potent and selective eIF4A inhibitor with anti-tumor activity in FGFR1,2 and HER2 driven cancers
    Thompson, Peggy A.
    Young, Nathan P.
    Gerson-Gurwitz, Adina
    Eam, Boreth
    Goel, Vikas
    Stumpf, Craig R.
    Chen, Joan
    Parker, Gregory S.
    Fish, Sarah
    Barrera, Maria
    Sung, Eric
    Staunton, Jocelyn
    Chiang, Gary G.
    Webster, Kevin R.
    CANCER RESEARCH, 2020, 80 (16)
  • [25] Anti-tumor activity of selinexor is enhanced by palbociclib in preclinical models of HER2+breast cancer
    Chang, Hua
    Friedlander, Sharon
    Kashyap, Trinayan
    Klebanov, Boris
    Argueta, Christian
    Gonzalez, Oscar A.
    Baloglu, Erkan
    Landesman, Yosef
    Shacham, Sharon
    Lee, Margaret
    Senapedis, William
    CANCER RESEARCH, 2017, 77
  • [26] Anti-tumor activity of tarloxotinib, a hypoxia-activated EGFR/HER2 TKI, in HER2 driven cell lines
    Estrada-Bernal, A.
    Le, A. T.
    Doak, A. E.
    Doebele, R. C.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E45 - E45
  • [27] HER2 status of circulating tumor cells in HER2-positive metastatic breast cancer patients: A valuable biomarker in anti-HER2 therapy
    Jiang, Z.
    Li, L.
    Liu, Y.
    Wang, T.
    Zhang, S.
    Yuan, Y.
    Bian, L.
    Liu, Q.
    Qi, F.
    CANCER RESEARCH, 2013, 73
  • [28] Dithiiranylmethyloxy azaxanthone shows potent anti-tumor activity via suppression of HER2 expression and HER2-mediated signals in HER2-overexpressing breast cancer cells
    Nam, Jung Min
    Jeon, Kyung-Hwa
    Kwon, Hanbyeol
    Lee, Eunyoung
    Jun, Kyu-Yeon
    Jin, Yeung Bae
    Lee, Yun-Sil
    Na, Younghwa
    Kwon, Youngjoo
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 50 (02) : 181 - 190
  • [29] Anti-tumor effect of Dasatinib in HER2 positive breast cancer with Trastuzumab resistance
    Takeda, Tatsuaki
    Kanzaki, Hirotaka
    Toyooka, Shinichi
    Watanabe, Mototsugu
    Ohtsuka, Tomoaki
    Suzawa, Ken
    Hashida, Shinsuke
    Maki, Yuho
    Yamamoto, Hiromasa
    Soh, Junichi
    Asano, Hiroaki
    Tsukuda, Kazunori
    Miyoshi, Shinichiro
    Kitamura, Yoshihisa
    Sendo, Toshiaki
    CANCER RESEARCH, 2015, 75
  • [30] Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer
    Li, Jianzong
    Wang, Haiyang
    Li, Junjie
    Bao, Jinku
    Wu, Chuanfang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (07)
12345